BACKGROUND: Pelizaeus-Merzbacher-like disease (PMLD) is a genetically heterogeneous disorder within the group of hypomyelinating leukoencephalopathies. Mutations of the gap junction protein alpha 12 (GJA12) gene are known to cause one autosomal recessive PMLD form. Few patients with GJA12 mutated PMLD have been reported, and to date, the frequency as well as the genotypic and phenotypic spectrum of GJA12 related PMLD is unclear. METHODS: We report mutation analysis of the GJA12 gene in a clinical and radiologic well-characterized multiethnic cohort of 193 patients with PMLD from 182 families. RESULTS AND CONCLUSIONS: Only 16 patients (8.3%) from 14 families (7.7%) carry GJA12 mutations including five families where we detected only one mutated allele. Among those, we identified 11 novel alterations. Thus, GJA12 mutations are a rather rare cause for Pelizaeus-Merzbacher-like disease. The clinical phenotype of patients with a GJA12 mutation was evaluated and is overall comparable to the clinical features seen in mild forms of proteolipid protein 1 (PLP1) related disorder but with better cognition and earlier signs of axonal degeneration.
BACKGROUND:Pelizaeus-Merzbacher-like disease (PMLD) is a genetically heterogeneous disorder within the group of hypomyelinating leukoencephalopathies. Mutations of the gap junction protein alpha 12 (GJA12) gene are known to cause one autosomal recessive PMLD form. Few patients with GJA12 mutated PMLD have been reported, and to date, the frequency as well as the genotypic and phenotypic spectrum of GJA12 related PMLD is unclear. METHODS: We report mutation analysis of the GJA12 gene in a clinical and radiologic well-characterized multiethnic cohort of 193 patients with PMLD from 182 families. RESULTS AND CONCLUSIONS: Only 16 patients (8.3%) from 14 families (7.7%) carry GJA12 mutations including five families where we detected only one mutated allele. Among those, we identified 11 novel alterations. Thus, GJA12 mutations are a rather rare cause for Pelizaeus-Merzbacher-like disease. The clinical phenotype of patients with a GJA12 mutation was evaluated and is overall comparable to the clinical features seen in mild forms of proteolipid protein 1 (PLP1) related disorder but with better cognition and earlier signs of axonal degeneration.
Authors: B Bilir; Z Yapici; C Yalcinkaya; I Baris; C M B Carvalho; M Bartnik; B Ozes; M Eraksoy; J R Lupski; E Battaloglu Journal: Clin Genet Date: 2012-02-20 Impact factor: 4.438
Authors: S Zittel; M Nickel; N I Wolf; G Uyanik; D Gläser; C Ganos; C Gerloff; A Münchau; A Kohlschütter Journal: J Neurol Date: 2012-07-26 Impact factor: 4.849
Authors: Tzipora C Falik Zaccai; David Savitzki; Yifat Zivony-Elboum; Thierry Vilboux; Eric C Fitts; Yishay Shoval; Limor Kalfon; Nadra Samra; Zohar Keren; Bella Gross; Natalia Chasnyk; Rachel Straussberg; James C Mullikin; Jamie K Teer; Dan Geiger; Daniel Kornitzer; Ora Bitterman-Deutsch; Abraham O Samson; Maki Wakamiya; Johnny W Peterson; Michelle L Kirtley; Iryna V Pinchuk; Wallace B Baze; William A Gahl; Robert Kleta; Yair Anikster; Ashok K Chopra Journal: Brain Date: 2016-12-21 Impact factor: 13.501
Authors: Stephanie J Munger; Xin Geng; R Sathish Srinivasan; Marlys H Witte; David L Paul; Alexander M Simon Journal: Dev Biol Date: 2016-03-04 Impact factor: 3.582
Authors: Jennifer L Orthmann-Murphy; Ettore Salsano; Charles K Abrams; Alberto Bizzi; Graziella Uziel; Mona M Freidin; Eleonora Lamantea; Massimo Zeviani; Steven S Scherer; Davide Pareyson Journal: Brain Date: 2008-12-04 Impact factor: 13.501